[A monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth. ( NCI )]
UMLS (NCI) C1328709 - Organic Chemical
- Pharmacologic Substance
- Immunologic Factor